Drug Profile

WVE 003

Alternative Names: mHTT SNP3; WVE-003

Latest Information Update: 18 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator WaVe life Sciences
Class Antidementias; Antisense oligonucleotides; Neuroprotectants
Mechanism of Action Gene silencing; Huntingtin protein expression inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Huntington's disease
New Molecular Entity Yes

Highest Development Phases

Phase I/II Huntington's disease

Most Recent Events

12 Nov 2024 WaVe life Sciences announces intention to submit an Investigational New Drug (IND) application for Huntington’s disease in the second half of 2025
12 Nov 2024 Wave Life Sciences receives initial feedback from the US FDA for WVE 003 in Huntington’s disease
12 Nov 2024 WVE 003 receives Orphan Drug status for Huntington's disease in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com